Share  |  Print  |  A A A
Home
To share a link to this page with a friend, colleague, or family member, please complete the form below:

Please complete both e-mail fields with valid addresses.




E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Thank you for sending an e-card about OPANA.com. Your e-card has been sent and the recipient(s) should receive an e-mail notification shortly.

Close


OPANA® ER for Managing Chronic Pain

No known CYP450 PK drug-drug interactions at clinically relevant doses1

True 12-hour dosing that lasts2

Minimal increase in pain scores (VAS) with a stable dose over a full 12 weeks in clinical trials3,4

Less supplemental rescue medication use than the allowable maximum in clinical trials3,4

Widely available on managed care plans (including Medicare Part D) for 8 out of 10 covered patients5

Over 1 million prescriptions written since 2006

Patient Profiles

Wanda, 46, Teacher

Wanda needs to control her pain while feeling comfortable with her medication
Download patient profile PDF

Mike, 53, Accountant

Mike needs more pain control to supplement his nonpharmacologic options       
Download patient profile PDF


Stella, 68, School Secretary

Stella needs improved pain control while managing the risk of drug interactions              
Download patient profile PDF

Bill, 40, Construction Worker

Bill needs a pain medication switch, because his Vicodin®* dose can’t be increased
Download patient profile PDF


Get Adode Reader

* Hydrocodone bitartrate and acetaminophen
Vicodin® is a registered trademark of Abbott Laboratories.

Select

Hydrocodone

Methadone

Morphine

Oxycodone

Oxymorphone


References

  1. OPANA ER Full Prescribing Information. Chadds Ford, Pa: Endo Pharmaceuticals; 2008.
  2. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004(4):468-476.
  3. Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8[2]:175-184.
  4. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naïve patients with chronic low back pain. Curr Med Res Opin. 2007;23:117-128.
  5. MediMedia Formulary Compass. http://www.formularycompass.com. Accessed December 31, 2008.